ProCE Banner Activity

Strategies to Mitigate Adverse Events with Asparaginase Treatment in Patients With ALL

Slideset Download
Download this slideset from a live CCO symposium for an expert overview on identifying and managing adverse events associated with asparaginase-based therapy in patients with ALL, including discussion of hepatotoxicity, thrombosis, pancreatitis, hypertriglyceridemia, and factors contributing to their development.

Released: December 15, 2021

Expiration: December 14, 2022

No longer available for credit.
Begin Activity



Wendy Susan Stevens

Wendy Susan Stevens

Professor and Head
Department of Molecular Medicine and Haematology
University of the Witswatersrand
Johannesburg, South Africa

Stephen Ansell

Stephen Ansell, MD, PhD

Associate Professor of Medicine
Department of Hematology
Mayo Clinical Cancer Center
Rochester, Minnesota

Danielle M. Brander

Danielle M. Brander, MD

Medical Instructor
Division of Hematologic Malignancies & Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina

Emily Bucholtz

Emily Bucholtz, RPh

Willamette Valley Cancer Institution
Eugene, Oregon

Lesley Scott

Lesley Scott

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Jazz Pharmaceuticals

Servier Oncology Global Medical and Patient Affairs

Servier Pharmaceuticals